Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALIMTA plus Epirubicin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ALIMTA plus Epirubicin | DRUG | - |
Inclusion Criteria: * Diagnosis of locally advanced or metastatic breast cancer not amenable to local treatment. * Patients must be chemo-naive or have only neoadjuvant and/or adjuvant chemotherapy. * Patients must have at least one measurable lesion in an area not previously irradiated. * No chemo...
Top 20 of 92 competitors
ALIMTA is an investigational oncology drug being studied for use in lung neoplasms, colorectal cancer, non-small-cell lung cancer, metastases, urologic neoplasms, and breast cancer. It is a small molecule developed by Eli Lilly and Company. Clinical trials have explored it in combination with other agents for these cancer types.
ALIMTA is developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is being investigated for multiple oncology indications including lung cancer, urologic neoplasms, and breast cancer.
ALIMTA is in Phase 2 clinical development. It is an investigational drug and is not approved by the FDA. Two Phase 2 trials have been completed, along with one Phase 1 trial, all of which are now finished.
ALIMTA has been studied in several completed clinical trials. NCT00034593 tested ALIMTA plus gemcitabine in transitional cell carcinoma of the urothelium. NCT00051493 evaluated ALIMTA plus carboplatin in non-small-cell lung cancer. NCT00051506 studied ALIMTA with cisplatin or carboplatin in small cell lung cancer. NCT00097383 examined ALIMTA with epirubicin in breast cancer.
ALIMTA is also known as pemetrexed. Clinical trial titles refer to ALIMTA (Pemetrexed) in combination with other chemotherapy agents. The drug is being investigated for multiple cancer types including non-small-cell lung cancer and breast cancer.